Skip to main content

Advertisement

Table 2 VEGF-A/VEGFR1, VEGF-A/VEGFR2, VEGF-B/VEGFR1, and VEGF-C/VEGFR2 ratios and association with clinico-pathological features in mismatch repair-proficient colorectal cancer.

From: Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer

   VEGF-A/VEGFR1 VEGF-A/VEGFR2 VEGF-B/VEGFR1 VEGF-C/VEGFR2
    P-value   P-value   P-value   P-value
TNM stage I+II 13.7 ± 32.6; 1.0 0.198 1.63 ± 8.6; 1.0 0.005 11.2 ± 27.2; 1.0 0.867 2.6 ± 9.3; 0.8 0.003
  III 13.0 ± 31.7; 1.0   0.66 ± 0.4; 0.95   8.1 ± 23.2; 1.0   0.58 ± 0.38; 0.68  
  IV 5.2 ± 19.7; 1.0   3.85 ± 16.3; 1.0   5.9 ± 20.0; 1.0   1.95 ± 8.8; 0.84  
Tumour grade G1-2 10.7 ± 29.2; 1.0 0.704 2.05 ± 10.6; 1.0 0.179 8.0 ± 22.9; 0.98 0.956 1.51 ± 8.2; 0.79 0.06
  G3 13.5 ± 32.2; 1.0   0.73 ± 0.4; 0.95   12.9 ± 29.7; 1.0   0.58 ± 0.4; 0.65  
Vascular invasion Absent 13.2 ± 32.2; 1.0 0.276 2.2 ± 11.3; 1.0 0.38 10.7 ± 26.9; 1.0 0.078 1.6 ± 8.9; 0.75 0.412
  Present 6.48 ± 22.0; 1.0   0.78 ± 0.36; 0.98   4.28 ± 15.2; 0.95   0.65 ± 0.38; 0.75  
Tumour border configuration PM 12.4 ± 31.2; 1.0 0.211 1.35 ± 6.3; 1.0 0.006 9.8 ± 25.2; 1.0 0.244 1.2 ± 5.7; 0.79 0.326
  IM 9.83 ± 27.6; 1.0   2.28 ± 12.2; 0.95   7.76 ± 23.2; 0.95   1.48 ± 9.04; 0.75  
PTL infiltration Absent 9.73 ± 27.6; 1.0 0.032 1.56 ± 8.4; 1.0 0.074 8.09 ± 23.5; 1.0 0.356 1.01 ± 4.5; 0.78 0.235
  Present 17.5 ± 36.6; 1.0   2.83 ± 13.6; 1.0   12.3 ± 27.5; 0.87   2.79 ± 14.7; 0.75  
  1. Mean ± SD, median values. Kruskal Wallis or Wilcoxon Rank Sum Test. PM = pushing/expanding margin; IM = infiltrating margin; PTL = peritumoral lymphocytic.